Researchers have reported for the first time a case of the autoimmune disorder antiphospholipid syndrome (APLS) in a woman who also developed cold agglutinin disease. More studies are needed to explore the possible relationship between the two conditions, according to authors of the…
News
Progressive hemolytic anemia — the rupture and gradual depletion of red blood cells — caused by cold agglutinin disease (CAD) was triggered in a man with diabetes being treated at a hospital with intravenous fluids, according to a case report. The man was admitted to the hospital…
Sutimlimab continues to lessen the need for blood transfusions, prevent red blood cell destruction, ease fatigue, and limit inflammation in patients with primary cold agglutinin disease (CAD), according to data from two Phase 3 trials. These findings will be presented by Sanofi, the investigational therapy’s developer, at…
Symptoms of cold agglutinin disease (CAD) worsened for a 57-year-old woman two days after receiving the first dose of a COVID-19 vaccine, and again two days after the second dose, a case study from Spain reported. In both instances, prednisone’s use eased her symptoms and restored normal values…
Cold agglutinin disease (CAD) is more frequently diagnosed during winter months at multiple locations across Europe, supporting outdoor temperature as a disease trigger, researchers reported. Findings also suggest that, in general, people living in places with milder weather may be less likely to experience CAD symptoms and, as such,…
A pregnant woman with a rare case of tuberculosis-induced cold autoimmune hemolytic anemia — also known as cold agglutinin disease (CAD) — was successfully treated with plasma exchange and medications for her tuberculosis. According to its authors, this “favorable…
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports. These findings…
A woman developed cold agglutinin disease (CAD) and myositis (muscle inflammation) as a complication of COVID-19, underscoring the importance of a timely, comprehensive evaluation to identify rare complications of SARS-CoV-2 infection. Researchers noted that the patient’s…
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each…
Sanofi’s investigational therapy sutimlimab safely and rapidly prevents red blood cell destruction (hemolysis), increases hemoglobin levels, and reduces fatigue in adults with primary cold agglutinin disease (CAD), according to full data from Part A of the Phase 3 CARDINAL study. These therapeutic benefits were associated with a fast and…
Recent Posts
- Cost-effective rituximab-based treatment keeps CAD at bay for years
- This year, ongoing CAD symptoms dampened my holiday cheer
- Immunochemotherapy can help control CAD but it carries safety risks
- Oral therapy iptacopan eases anemia in CAD patients: Small trial
- When living with CAD, even a short trip can be a nightmare
- Real-world study confirms long-term safety of Enjaymo for CAD
- After months of fatigue, feeling better is what I want for Christmas
- Man’s case shows bacterial lung infection can ‘provoke’ clots, CAD
- Living with cold agglutinin disease involves cruel curveballs
- Gastric lymphoma found to be hidden cause of refractory CAD